Abstract
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event for patients with cancer. Many advances over the past 2 decades have improved the treatment of CINV, thus increasing the quality of life of cancer patients. Understanding the pathophysiology and risk factors for CINV helps clinicians develop better treatments and strategies for prevention. Updates to the understanding and management of CINV occur very often due to intense study and interest in this common toxicity associated with cancer therapy. As a result, the optimal management of CINV changes continually, impacting patient care. Oncology advanced practitioners (APs) are often the primary contact and treating providers of CINV. This article will review the most recent updates in risk factors, pathophysiology, classifications, treatments, and changes incorporated into guidelines for the management of CINV, providing opportunities for APs to better understand and treat CINV.
